UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

ATAI Life Sciences N.V.

(Name of Issuer)

Common Shares (Title of Class of Securities)

N0731H103

(CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

 $\square Rule 13d-1(b)$ $\square Rule 13d-1(c)$ $\square Rule 13d-1(d)$

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. N0731H103

(1)	Names of reporting persons:				
	Galaxy	Group	Funding (ECI) (U) LLC		
(2)	opriate box if a member of a group (see instructions) (a) (b)				
(3)	SEC us	e only			
(4)	Citizen	Citizenship or place of organization:			
	Delawa	are			
		(5)	Sole voting power:		
s	nber of hares	(6)	0 Shared voting power:		
beneficially owned by			10,796,736		
6	each	(7)	Sole dispositive power:		
	oorting on with		0		
pers		(8)	Shared dispositive power:		
			10,796,736		
(9)	Aggreg	ate amo	unt beneficially owned by each reporting person:		
	10,796,	,736			
(10) Check if the aggregate amount in row (9) excludes certain shares (see instructions):		gregate amount in row (9) excludes certain shares (see instructions):			
(11)	Percent	of class	s represented by amount in row (9):		
	6.7%				
(12) Type of reporting person (see instructions):			ng person (see instructions):		
	00				
L					

CUSIP No. N0731H103

(1)	Names of reporting persons:			
	Galaxy	Group	Investments LLC	
(2)				(a) □ (b) □
(3)	SEC use only			(-)
(4)	Citizenship or place of organization:			
	Delawa	re		
		(5)	Sole voting power:	
sł bene	nber of nares eficially ned by	(6)	Shared voting power: 10,796,736	
e rep	each each orting on with	(7)	Sole dispositive power: 0	
pers	on with	(8)	Shared dispositive power:	
(9)	Aggreg	ate amo	10,796,736 unt beneficially owned by each reporting person:	
	10,796,			
(10)	Check if the aggregate amount in row (9) excludes certain shares (see instructions):			
(11)	Percent of class represented by amount in row (9): 6.7%			
(12)		reporti	ng person (see instructions):	

CUSIP No. N0731H103

(1)	Names of reporting persons:			
	Michae	el E. No	vogratz	
(2)) 🗆
(3)	SEC use only			
(4)	Citizens	Citizenship or place of organization:		
	Delawa	ire		
		(5)	Sole voting power:	
sl bene	nber of hares eficially	(6)	Shared voting power: 10,796,736	
e rep	ned by each oorting	(7)	Sole dispositive power:	
pers	on with	(8)	Shared dispositive power:	
			10,796,736	
(9)	Aggreg	ate amo	unt beneficially owned by each reporting person:	
	10,796,	736		
(10)	Check if the aggregate amount in row (9) excludes certain shares (see instructions):			
(11)	Percent of class represented by amount in row (9): 6.7%			
(12)	Type of reporting person (see instructions):			

Item 1(a). Name of issuer:

ATAI Life Sciences N.V. (the "Issuer")

Item 1(b). Address of issuer's principal executive offices:

ATAI Life Sciences N.V. c/o Mindspace Krausenstraße 9-10 Berlin, Germany

Item 2(a). Name of person filing:

This Schedule 13G is being filed by: (i) Galaxy Group Funding (ECI) (U) LLC, a Delaware limited liability company ("GGF"), (ii) Galaxy Group Investments LLC, a Delaware limited liability company ("GGI"), and (iii) Michael E. Novogratz (all of the foregoing, collectively, the "Reporting Persons"). GGF is the holder of record of the Common Shares reported in this Schedule 13G. GGI is the manager of GGF and Michael E. Novogratz is the manager of GGI. GGI and Michael E. Novogratz may be deemed to share beneficial ownership of the Common Shares held of record by GGF.

Item 2(b). Address of principal business office or, if none, residence:

The principal business office of the Reporting Persons is:

107 Grand Street, 7th Floor New York, NY 10013

Item 2(c). Citizenship:

GGF and GGI are limited liability companies organized in Delaware.

Michael E. Novogratz is a United States citizen.

Item 2(d). Title of Class of Securities:

Common Shares, par value €0.10 per share ("Common Shares")

Item 2(e). CUSIP No.:

N0731H103

Item 3.

Not Applicable.

Item 4. Ownership

The ownership information below represents beneficial ownership by the Reporting Persons of the Common Shares of the Issuer as of December 31, 2021, based upon 160,297,952 Common Shares outstanding as of November 1, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on November 15, 2021.

Item 5. Ownership of Five Percent or Less of a Class

Not Applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certification

Not Applicable.

Exhibit No.	Document
99.1	Joint Filing Agreement, dated February 22, 2022, among the Reporting Persons

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	Galaxy Group Funding (ECI) (U) LLC
February 22, 2022	By:/s/ Vincent BarbutoName:Vincent BarbutoTitle:Chief Financial Officer
	Galaxy Group Investments LLC
February 22, 2022	By:/s/ Vincent BarbutoName:Vincent BarbutoTitle:Chief Financial Officer
February 22, 2022	By: /s/ Michael E. Novogratz Name: Michael E. Novogratz

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Shares of ATAI Life Sciences N.V. beneficially owned by each of them, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statements on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of February 22, 2022.

C	alaxy Group Funding (ECI) (U) LLC
Ν	y: /s/ Vincent Barbuto ame: Vincent Barbuto itle: Chief Financial Officer
G	alaxy Group Investments LLC
N	y: <u>/s/ Vincent Barbuto</u> ame: Vincent Barbuto itle: Chief Financial Officer
	y: /s/ Michael E. Novogratz ame: Michael E. Novogratz